# Assessment of Effect of Rapastinel on Driving Performance

> **NCT03814733** · PHASE1 · COMPLETED · sponsor: **Naurex, Inc, an affiliate of Allergan plc** · enrollment: 107 (actual)

## Conditions studied

- Driving Performance

## Interventions

- **DRUG:** Rapastinel
- **DRUG:** Alprazolam
- **DRUG:** Ketamine
- **DRUG:** Rapastinel Matched Placebo
- **DRUG:** Alprazolam Matched Placebo
- **DRUG:** Ketamine Matched Placebo

## Key facts

- **NCT ID:** NCT03814733
- **Lead sponsor:** Naurex, Inc, an affiliate of Allergan plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-05
- **Primary completion:** 2019-03-29
- **Final completion:** 2019-04-03
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2019-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03814733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03814733, "Assessment of Effect of Rapastinel on Driving Performance". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03814733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*